Corium International Inc (NASDAQ:CORI) – Stock analysts at Cantor Fitzgerald reduced their FY2018 earnings per share estimates for Corium International in a report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now expects that the biopharmaceutical company will post earnings of ($1.32) per share for the year, down from their prior estimate of ($1.19). Cantor Fitzgerald has a “Buy” rating and a $14.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Corium International’s FY2019 earnings at ($0.94) EPS.
Corium International (NASDAQ:CORI) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The firm had revenue of $9.32 million during the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%.
Corium International (CORI) traded up $0.05 during mid-day trading on Wednesday, reaching $11.91. The company’s stock had a trading volume of 7,342 shares, compared to its average volume of 266,947. The company has a debt-to-equity ratio of 5.91, a current ratio of 1.40 and a quick ratio of 1.34. The company has a market capitalization of $441.80, a PE ratio of -7.51 and a beta of 1.50. Corium International has a 12 month low of $3.50 and a 12 month high of $13.93.
Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new position in Corium International during the fourth quarter worth about $123,000. New York State Common Retirement Fund acquired a new position in Corium International during the second quarter worth about $158,000. California State Teachers Retirement System acquired a new position in Corium International during the second quarter worth about $263,000. Teachers Advisors LLC acquired a new position in Corium International during the second quarter worth about $272,000. Finally, California Public Employees Retirement System acquired a new position in Corium International during the fourth quarter worth about $310,000. 88.58% of the stock is currently owned by hedge funds and other institutional investors.
In other news, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the stock in a transaction that occurred on Thursday, January 18th. The shares were purchased at an average cost of $12.54 per share, with a total value of $6,395,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Perceptive Advisors Llc bought 50,350 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. 30.80% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/cantor-fitzgerald-comments-on-corium-international-incs-fy2018-earnings-cori.html.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.